Campylobacter infection in 4 patients treated with ibrutinib

Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in B-cell lymphoproliferative disorders. Patients with genetic BTK deficiency are susceptible to recurrent and severe Campylobacter infections. We report 4 patients treated with ibrutinib who developed chronic or extra-digestive campylobacte...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical microbiology & infectious diseases 2022-05, Vol.41 (5), p.849-852
Main Authors: Sorin, Boris, Vigneron, Julien, Fadlallah, Jehane, Mondesir, Johanna, Fieschi, Claire, Oksenhendler, Eric, Galicier, Lionel, Malphettes, Marion
Format: Article
Language:English
Subjects:
Antibiotics
Arthritis
Biomedical and Life Sciences
Biomedicine
Brief Report
Bruton's tyrosine kinase
Campylobacter
Campylobacteriosis
Diarrhea
Enzyme inhibitors
Immunoproliferative diseases
Internal Medicine
Kinases
Lymphatic diseases
Lymphocytes
Lymphocytes B
Medical Microbiology
Protein-tyrosine kinase
Signs and symptoms
Tyrosine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in B-cell lymphoproliferative disorders. Patients with genetic BTK deficiency are susceptible to recurrent and severe Campylobacter infections. We report 4 patients treated with ibrutinib who developed chronic or extra-digestive campylobacteriosis resembling ibrutinib-related adverse events including diarrhea ( n  = 4), panniculitis ( n  = 2), and arthritis ( n  = 1). Microbiological explorations identified Campylobacter jejuni ( n  = 3) or Campylobacter coli ( n  = 1). All the patients completely recovered after a short course of oral antibiotic therapy. In patients treated with ibrutinib presenting with chronic diarrhea, dermatological, or rheumatological manifestations, campylobacteriosis should be ruled out before attributing the symptoms to ibrutinib and discuss its discontinuation.
ISSN:0934-9723
1435-4373
DOI:10.1007/s10096-022-04433-4